Mari Tuyama

Mari Tuyama

Auto-generated profile, based on publicly available information

Mari Tuyama

Fundação Oswaldo Cruz, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
FCFlavio de Carvalho
Flavio de Carvalho
LBLuciana Gomes Pedro Brandão
Luciana Gomes Pedro Brandão
MVMargaret Catoia Varela
Margaret Catoia Varela
MTMari Tuyama
Mari Tuyama
DCDanusa Ferreira Correa
Danusa Ferreira Correa
PBPedro Emmanuel Alvarenga Americano do Brasil
Pedro Emmanuel Alvarenga Americano do Brasil
The objectives were to estimate hepatitis A virus seroprevalence in subjects attending to a travel medicine and immunization clinic in Rio de Janeiro, Brazil, and to develop a prediction model for hepatitis A virus seroprevalence. This retrospective research included individuals sequentially from April 2011 to June 2019 at a travel medicine and special population immunization clinic with an anti-hepatitis A virus IgG chemiluminescence result. Participants’ data were verified via electronic medical records. Data were split into development and validation set taking 2018 as the date break. A cross-validated elastic generalized linear model with binomial distribution was performed. In total, 2,944 subjects were analyzed. Hepatitis A virus overall seroprevalence was 67.8%. Health professionals, travelers, and those who had contact with immunocompromised subjects had lower seroprevalence (40%-55%), whereas subjects with chronic conditions (heart, lung, and liver) ranged from 89% to 94%. The retained predictors in the final model were sex, age, year of birth, travelers, HIV/AIDS, spleen dysfunction, transplant candidates, household communicators, cancer-related immunosuppression, health care professionals. Area under the curve was 0.836 and maximum error was 0.051. Users can make predictions with the following calculator: https://pedrobrasil.shinyapps.io/INDWELL/. The groups with lower seroprevalence should be evaluated more carefully regarding need for hepatitis A virus vaccination even when they seek immunization clinics for other purposes.

1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
KBKonrad Silva Büchele
Konrad Silva Büchele
DCDanusa Ferreira Correa
Danusa Ferreira Correa
MTMari Tuyama
Mari Tuyama
ALAlberto dos Santos de Lemos
Alberto dos Santos de Lemos
MCMarcellus Dias da Costa
Marcellus Dias da Costa
LBLuciana Gomes Pedro Brandão
Luciana Gomes Pedro Brandão
Varicella in adults and immunocompromised patients can be severe. The clinical diagnosis of varicella has high accuracy and the history of disease has a high positive predictive value for protection. A significant portion of adults, however, cannot remember if they have had varicella, especially older individuals. We conducted a cross-sectional study to determine the seroprevalence of varicella protective antibodies titers in adults with no clinical history of disease, attended at a Reference Center for Special Immunobiologicals and Travel Medicine in Rio de Janeiro (Brazil). Titration of immunoglobulin G (IgG) antibodies to varicella-zoster was determined by chemiluminescence immunoassay. Among 140 adults without history of varicella, 92% had protective antibody titers. We concluded that seroprevalence of varicella-zoster protection was very high in adults with negative history of disease and the use of serology before vaccination reduced significantly unnecessary vaccine and immunoglobulin use.